Seattle Genetics to Webcast Virtual Fireside Chat at Barclays Global Healthcare Conference
March 10 2020 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay
Siegall, Ph.D., President and Chief Executive Officer, will
participate in a fireside chat at the Barclays Global Healthcare
Conference on Wednesday, March 11, 2020 at 4:20 p.m. Eastern Time.
The conference will be held in a virtual meeting format. The
presentation will be webcast live and available for replay from
Seattle Genetics’ website at www.seattlegenetics.com in the
Investors section.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that
discovers, develops and commercializes transformative medicines
targeting cancer to make a meaningful difference in people’s lives.
ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab
vedotin-ejfv) use the company’s industry-leading antibody-drug
conjugate (ADC) technology. ADCETRIS is approved in certain
CD30-expressing lymphomas, and PADCEV is approved in certain
metastatic urothelial cancers. In addition, investigational agent
tucatinib, a small molecule tyrosine kinase inhibitor, is in
late-stage development for HER2-positive metastatic breast cancer
and in clinical development for metastatic colorectal cancer. The
company is headquartered in Bothell, Washington, and has offices in
California, Switzerland and the European Union. For more
information on our robust pipeline, visit www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200310005255/en/
Investors: Peggy Pinkston (425) 527-4160 ppinkston@seagen.com
Media: Monique Greer (425) 527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024